Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide maintenance after allo-HSCT for high-risk acute myeloid leukemia
ChiCTR2100050400Phase 2Recruiting
- Sponsor
- Aerospace Center Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in acute myeloid leukemia (AML), sponsored by Aerospace Center Hospital. Primary endpoint: 2-year cumulative recurrence rate. Started Aug 2021; status: recruiting.
02
Drugs
tucidinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100050400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050400.